Items Tagged ‘daratumumab’

December 13th, 2017

Addition of Darzalex™ Improves Outcomes in Newly Diagnosed Multiple Myeloma

By

The addition of Darzalex (daratumumab) to the standard treatment combination consisting of Velcade (bortezomib), melphalan, and prednisone (VMP) reduces disease progression or death by 50%, among patients with newly diagnosed multiple myeloma who are not eligible to undergo a stem cell transplant. These results were presented as a late-breaking abstract at the 2017 annual meeting […]

View full entry

Tags: bortezomib, daratumumab, Darzalex, melphalan, Multiple Myeloma, News, Precision Cancer Medicine, prednisone, velcade, VMP


July 7th, 2016

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma

By

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently published in the journal Blood. Multiple myeloma is a type of blood cancer that affects certain immune cells called plasma cells. Healthy plasma cells produce proteins called antibodies that […]

View full entry

Tags: blood cancer, daratumumab, Darxalex, IMid, Multiple Myeloma, News, PI, proteasome inhibitor, Recurrent Multiple Myeloma, Stages II-III Multiple Myeloma


September 17th, 2015

Daratumumab Effective in Multiple Myeloma

By

The targeted agent, daratumumab, which is still in clinical trials, appears to be effective in patients with multiple myeloma that has stopped responding to standard therapies. These results were recently published in the New England Journal of Medicine. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell […]

View full entry

Tags: clinical trial, daratumumab, Multiple Myeloma, News, Recurrent Multiple Myeloma, refactory


September 2nd, 2015

Immunotherapy Benefits Patients with Drug-Resistant Multiple Myeloma

By

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine. The drug, daratumumab, proved generally safe in patients even […]

View full entry

Tags: antibody therapy, clinical trial, daratumumab, monoclonal antibody, Multiple Myeloma, News, Recurrent Multiple Myeloma


December 15th, 2014

Daratumumab Anti-CD38 Monoclonal Antibody Appears Promising For the Treatment of Multiple Myeloma

By

An investigational new class of drugs, the anti-CD38 monoclonal antibodies, could be the next major advance in the treatment of multiple myeloma. These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California. Multiple myeloma is a cancer of plasma cells, which are a special […]

View full entry

Tags: anti-CD38, daratumumab, Multiple Myeloma, News, Recurrent Multiple Myeloma